Genomma Lab Internacional (LABB) Corporate presentation summary

Business overview

• Develops, manufactures, and markets a portfolio of 60 premium branded products for mass consumption, with many category leaders.

• Operates across OTC, personal care, and beverages, with 51% of business in OTC and 47% in personal care.

• Strong geographical footprint: 47% of sales in Mexico, 44% in Latin America, and 9% in the US.

• Robust distribution network covers traditional channels, pharmacies, supermarkets, discounters, and convenience stores.

• State-of-the-art manufacturing facility supported by international financing and focused on high product quality and reliable supply.

Brand and product portfolio

• Leading OTC brands in cough & cold, analgesics, derma OTC, gastro, and infant nutrition.

• Personal care brands include Medicasp, Tio Nacho, Vanart, Cicatricure, Goicoechea, Teatrical, and Asepxia.

• Beverage portfolio led by Suerox, offering a variety of sugar-free, electrolyte-rich drinks.

• Ongoing product innovation across all categories, with new forms, improved formulas, and expanded routines.

• Strong OTC registry pipeline with increasing submissions and approvals.

Financial performance and growth

• Consolidated net sales have grown at a 5.5% CAGR, with EBITDA at 8.8% CAGR.

• Gross margin expected to rise from 60.4% in 2022 to 62.8% in 2025; EBITDA margin from 20.5% to 23.4%.

• EPS projected to increase 21% from MXN $1.33 to $1.61 by 2025; ROIC to improve from 13.5% to 15.0%.

• Delivered MXN $1.1B in productivity to self-fund growth investments and support the 2026 recovery plan.

• Disciplined plan targeting MXN $1.4B incremental sales through innovation, execution, and channel expansion.